Plain-English translation of NCT06435286 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new artificial intelligence-powered mobile microscope called the AI-mHRME to help doctors spot early esophageal cancer more accurately. Right now, doctors use a standard procedure called Lugol's chromoendoscopy to look for cancer signs in the food pipe. This study will see if the new AI microscope tool can find cancerous changes better than the standard method alone, and whether it can reduce the number of biopsies patients need.
Early detection of esophageal cancer saves lives, but the current screening method sometimes misses changes or requires many unnecessary biopsies. Researchers hope this new artificial intelligence-powered microscope will help doctors make faster, more accurate decisions about who really needs a biopsy.
You likely qualify if…
You likely don't qualify if…
You will come for an upper endoscopy procedure (a camera exam of your food pipe), which is the standard cancer screening test. During this visit, doctors will first do the usual screening with a dye called Lugol's chromoendoscopy. Then they will use the new AI-powered microscope tool to image any abnormal areas and normal areas found during screening. Finally, abnormal areas will be biopsied (a small tissue sample taken) so doctors can examine them under a microscope to confirm if cancer is present. The entire procedure typically takes about 30–60 minutes, and you will receive sedation to keep you comfortable.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States
Brazil